Literature DB >> 9884347

Local delivery of TNF by retrovirus-transduced T lymphocytes exacerbates experimental autoimmune encephalomyelitis.

R A Dal Canto1, M K Shaw, G P Nolan, L Steinman, C G Fathman.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an inflammatory autoimmune disease of the central nervous system that serves as a model for the human disease multiple sclerosis. Paralysis is "induced" by CD4+ T cells of the Th1 phenotype. Tumor necrosis factor (TNF), a Th1 type cytokine, has been shown to be upregulated in the CNS during the onset of EAE, and systemic manipulations of TNF have had substantial effects on disease progression. However, the precise role of TNF in EAE has been called into question by recent experiments utilizing TNF and lymphotoxin knockout mice. We demonstrate here that the local delivery of TNF by myelin basic protein (MBP)-specific T cells, retrovirally transduced to express TNF, exacerbated MBP-induced disease following adoptive transfer into syngeneic mice. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9884347     DOI: 10.1006/clim.1998.4653

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

Review 1.  The role of TNFalpha and lymphotoxin in demyelinating disease.

Authors:  C Lock; J Oksenberg; L Steinman
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

3.  Noncoding RNAs and LRRFIP1 regulate TNF expression.

Authors:  Lihua Shi; Li Song; Michael Fitzgerald; Kelly Maurer; Asen Bagashev; Kathleen E Sullivan
Journal:  J Immunol       Date:  2014-02-24       Impact factor: 5.422

Review 4.  Gene therapy in experimental autoimmune encephalomyelitis.

Authors:  P M Mathisen; V K Tuohy
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

5.  Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination.

Authors:  Roberta Brambilla; Jessica Jopek Ashbaugh; Roberta Magliozzi; Anna Dellarole; Shaffiat Karmally; David E Szymkowski; John R Bethea
Journal:  Brain       Date:  2011-09       Impact factor: 13.501

6.  Rig is a novel Ras-related protein and potential neural tumor suppressor.

Authors:  Chad A Ellis; Michele D Vos; Heather Howell; Teresa Vallecorsa; Daniel W Fults; Geoffrey J Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-09       Impact factor: 11.205

Review 7.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

8.  Interaction of disease-related antigen-reactive T-cell lines from multiple sclerosis patients with type IV collagen: role of integrin VLA-1 and effects of irradiation.

Authors:  Ilan Bank; Anat Achiron; Gad Levie; Alexander Koltakov; Mathilda Mandel
Journal:  J Clin Immunol       Date:  2002-05       Impact factor: 8.317

9.  Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination.

Authors:  Pernille M Madsen; Dario Motti; Shaffiat Karmally; David E Szymkowski; Kate Lykke Lambertsen; John R Bethea; Roberta Brambilla
Journal:  J Neurosci       Date:  2016-05-04       Impact factor: 6.167

10.  Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins.

Authors:  Sarah M Short; Alexandrine Derrien; Radha P Narsimhan; Jack Lawler; Donald E Ingber; Bruce R Zetter
Journal:  J Cell Biol       Date:  2005-02-14       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.